Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $4B; returns 1 day -3.1%, 1 week +8.3%, 1 year +55.4%.

Arcutis Biotherapeutics Inc. is a commercial-stage biopharmaceutical company specializing in immuno-dermatology, focused on developing and commercializing innovative topical and biologic therapies for chronic inflammatory skin diseases. The company's primary revenue driver is its ZORYVE (roflumilast) franchise, a Phosphodiesterase-4 (PDE4) inhibitor, which is marketed in various formulations.

Groups ARQT belongs to

• Dermatology
• Biotechnology
• Biopharmaceutical
• Commercial Stage Biotech
• Chronic Inflammatory Diseases
• Healthcare
• Pharmaceuticals
• Commercial Stage
• Autoimmune Diseases
• Immunotherapy

ARQT financial model: income statement, cash flow and balance sheet